Chen Wan-Jun, Wang Bing, Han Xiu-Li
Department of Head and Neck Surgery, Shandong Tumor Hospital, Shandong Academy of Medical Sciences, Jinan.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Jul;32(7):892-5.
To study the adjunctive roles of Qingliu Lianghou Recipe (QLR) in treatment of hypopharyngeal carcinoma.
A total of 156 patients with hypopharyngeal squamous cell carcinoma were recruited, including 21 cases of stage I, 34 in stage II, 55 in stage III, and 46 in stage IV. Of them, 31 patients (Group A) were managed with operation and post-operative radiotherapy, 40 patients (Group B) with operation, post-operative radiotherapy, and QLR, 45 patients (Group C) were managed with concomitant chemoradiotherapy, 40 patients (Group D)with concomitant chemoradiation and QLR. QLR was given for 12 weeks. The radio- and chemotoxic reactions, quality of life (KPS score), and long-term efficacy (the recurrence time and the survival time) were observed.
The toxicity levels were significantly lower in Group B than in Group A, manifested as radioactive dermatitis, mucositis, dysphagia, changes in body weight, and lymphatic edema (P < 0.05, P < 0.01). The toxicity levels were significantly lower in Group D than in Group C, manifested as radioactive dermatitis, mucositis, dysphagia, marrow depression, changes in body weight, and gastrointestinal reactions (P < 0.05, P < 0.01). After treatment the KPS scores of all patients obviously decreased (P < 0.05, P < 0.01). But the KPS scores were significantly higher in Group B than in Group A (P < 0.05), and they were significantly higher in Group D than in Group C (P < 0.05). The 3-year recurrence rate of patients in Group A was 41.94%, 20.00% in Group B, 60.00% in Group C, and 37.50% in Group D (P < 0.05). The 5-year survival rate of patients in Group A was 38.71%, 62.50% in Group B, 22.22% in Group C, and 42.50% in Group D (P < 0.05).
QLR could effectively prevent and reduce the toxicity response caused by operation, radiotherapy and chemotherapy. The combination therapy of integrative medicine could postpone the recurrence and prolong the lifespan of patients. Therefore, we must not neglect the adjunctive therapy of QLR in treating hypopharyngeal carcinoma.
探讨清瘤凉喉方（QLR）在下咽癌治疗中的辅助作用。
共纳入156例下咽鳞状细胞癌患者，其中Ⅰ期21例，Ⅱ期34例，Ⅲ期55例，Ⅳ期46例。其中，31例患者（A组）接受手术及术后放疗，40例患者（B组）接受手术、术后放疗及QLR治疗，45例患者（C组）接受同步放化疗，40例患者（D组）接受同步放化疗及QLR治疗。QLR给药12周。观察放疗和化疗毒性反应、生活质量（KPS评分）及远期疗效（复发时间和生存时间）。
B组毒性水平显著低于A组，表现为放射性皮炎、黏膜炎、吞咽困难、体重变化及淋巴水肿（P<0.05，P<0.01）。D组毒性水平显著低于C组，表现为放射性皮炎、黏膜炎、吞咽困难、骨髓抑制、体重变化及胃肠道反应（P<0.05，P<0.01）。治疗后所有患者的KPS评分均明显下降（P<0.05，P<0.01）。但B组KPS评分显著高于A组（P<0.05），D组KPS评分显著高于C组（P<0.05）。A组患者3年复发率为41.94%，B组为20.00%，C组为60.00%，D组为37.50%（P<0.05）。A组患者5年生存率为38.71%，B组为62.50%，C组为22.22%，D组为42.50%（P<0.05）。
QLR可有效预防和降低手术、放疗及化疗引起的毒性反应。中西医结合治疗可延缓患者复发，延长患者生存期。因此，在下咽癌治疗中不可忽视QLR的辅助治疗作用。
